Skip to main navigation

Top Bar

  • info@eledon.com
  • +1 949.238.8090
Eledon Pharmaceuticals - logo

Main navigation

  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Governance
  • R&D
    • R&D Overview
    • CD40L Pathway
    • Pipeline
    • AT-1501
    • Phase 1 KLH Challenge
  • Investors
    • News
    • Events
    • Presentations
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
    • Contact
  • Join the team
  • Contact Us

Investors

Investor Relations

  • Investors
  • News
  • Events
  • Presentations
  • Stock Information
  • Analyst Coverage
  • SEC Filings
  • Corporate Governance
  • Investor FAQs
  • Contact Investor Relations
  • Ethics Hotline

Presentations


Corporate Presentations
Eledon Corporate Presentation
ALS Phase 2a Clinical Trial Update Presentation
Eledon Pharmaceuticals R&D Day Presentation
Scientific Presentations
2021 International Pancreas and Islet Transplantation Association Congress
A Phase 2 Safety and Tolerability Study of an Anti CD40L Antibody, AT-1501 in Adults with ALS
2021 American Transplant Congress
The Development and Characterization of AT-1501, an Anti-CD40L Antibody Lacking Fc Effector Function
Pharmacokinetic and Toxicity Studies of an Anti-CD40L Antibody, AT-1501 in Rhesus Macaques
CSS

Toolkit

Print Page Email Alerts RSS Feeds Contact

Footer

Quick links

  • Home
  • About Us
  • CD40L Pathway
  • Pipeline
  • AT-1501
  • KLH Challenge
  • Contact Us

Footer Investor Links

  • Investors
  • Press Releases
  • Governance
  • Stock Information
  • SEC Filings
  • Investor Email List
© 2023 Eledon Pharmaceuticals, Inc. - All Rights Reserved.